X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
urologi och njurmedicin (2980) 2980
urology and nephrology (2923) 2923
klinisk medicin (2347) 2347
medicin och hälsovetenskap (2301) 2301
clinical medicine (2298) 2298
medical and health sciences (2245) 2245
humans (1302) 1302
urology & nephrology (1118) 1118
male (1086) 1086
female (656) 656
middle aged (634) 634
aged (607) 607
cancer och onkologi (485) 485
prostate cancer (485) 485
cancer and oncology (478) 478
adult (362) 362
urology (326) 326
animals (267) 267
cancer (265) 265
risk factors (252) 252
aged, 80 and over (230) 230
surgery (222) 222
mortality (209) 209
treatment outcome (198) 198
prognosis (175) 175
diagnosis (167) 167
research (166) 166
prostatic neoplasms - pathology (164) 164
time factors (161) 161
oncology (158) 158
men (154) 154
sweden (151) 151
bladder cancer (143) 143
rats (143) 143
prostate-specific antigen - blood (142) 142
survival (139) 139
analysis (135) 135
medicine (135) 135
risk (135) 135
nephrology (134) 134
health aspects (133) 133
medicinska och farmaceutiska grundvetenskaper (132) 132
retrospective studies (131) 131
radical prostatectomy (129) 129
prospective studies (125) 125
prostatic neoplasms - diagnosis (123) 123
prostatic neoplasms (122) 122
sweden - epidemiology (119) 119
basic medicine (118) 118
follow-up studies (118) 118
biopsy (117) 117
glomerular filtration rate (116) 116
transplantation (115) 115
epidemiology (114) 114
care and treatment (112) 112
adolescent (109) 109
disease (108) 108
physiology (106) 106
prostate-specific antigen (105) 105
quality of life (103) 103
prostate (102) 102
prostatic neoplasms - blood (101) 101
kirurgi (99) 99
incidence (95) 95
neoplasm staging (94) 94
expression (92) 92
prevalence (90) 90
complications (88) 88
abridged index medicus (87) 87
bladder (85) 85
immunohistochemistry (85) 85
kidney diseases (84) 84
pediatrics (84) 84
carcinoma (83) 83
chronic kidney disease (83) 83
therapy (83) 83
cohort studies (82) 82
disease progression (82) 82
mice (81) 81
follow-up (80) 80
management (79) 79
risk assessment (79) 79
oncology, experimental (78) 78
pathology (78) 78
pediatrik (78) 78
quality-of-life (78) 78
outcomes (76) 76
patients (76) 76
medicin (75) 75
predictive value of tests (75) 75
prostatic neoplasms - mortality (75) 75
child (74) 74
progression (74) 74
recurrence (74) 74
hemodialysis (72) 72
rats, sprague-dawley (72) 72
prostatectomy (71) 71
tumors (71) 71
young adult (71) 71
kidney (70) 70
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2956) 2956
Swedish (20) 20
German (9) 9
French (2) 2
Norwegian (1) 1
Portuguese (1) 1
Russian (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2018, Volume 378, Issue 19, pp. 1767 - 1777
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2014, Volume 384, Issue 9959, pp. 2027 - 2035
Summary Background The European Randomised study of Screening for Prostate Cancer (ERSPC) has shown significant reductions in prostate cancer mortality after 9... 
Internal Medicine | TRIAL | MEDICINE, GENERAL & INTERNAL | RISK | DEATH | BIOPSY | ANTIGEN | Follow-Up Studies | Europe | Humans | Middle Aged | Male | Aged | Prostatic Neoplasms - diagnosis | Prostate-Specific Antigen - analysis | Prostatic Neoplasms - mortality | Medical screening | Prostate cancer | Mortality | Age | Men | Urologi och njurmedicin | Cancer and Oncology | Urology and Nephrology | Cancer och onkologi
Journal Article
Journal Article
European urology, ISSN 0302-2838, 2017, Volume 72, Issue 4, pp. 544 - 554
Journal Article
European urology, ISSN 0302-2838, 2019, Volume 76, Issue 1, pp. 43 - 51
The European Randomized study of Screening for Prostate Cancer (ERSPC) has previously demonstrated that prostate-specific antigen (PSA) screening decreases... 
Screening | Prostate-specific antigen | Prostate cancer | Mortality | UROLOGY & NEPHROLOGY | RISK | DEATH | ERSPC | Research | Diagnosis | Oncology, Experimental | Analysis | Cancer | Urologi och njurmedicin | death | mets dl | statistics in medicine | Urology & Nephrology | p1341 | 1994 | v13 | risk | Urology and Nephrology | erspc
Journal Article
The New England journal of medicine, ISSN 0028-4793, 2019, Volume 381, Issue 1, pp. 13 - 24
A randomized trial tested whether the addition of apalutamide, an androgen receptor blocker, to androgen-deprivation therapy might improve radiographic... 
SURVIVAL | MEDICINE, GENERAL & INTERNAL | THERAPY | ANTIANDROGEN | FUNCTIONAL ASSESSMENT | QUALITY-OF-LIFE | DOCETAXEL | Adenocarcinoma - pathology | Androgen Receptor Antagonists - therapeutic use | Humans | Middle Aged | Male | Androgen Receptor Antagonists - adverse effects | Thiohydantoins - adverse effects | Neoplasm Grading | Exanthema - chemically induced | Thiohydantoins - therapeutic use | Aged, 80 and over | Adult | Prostatic Neoplasms - drug therapy | Prostatic Neoplasms - pathology | Double-Blind Method | Kaplan-Meier Estimate | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Prostatic Neoplasms - mortality | Radiography | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Progression-Free Survival | Androgen Antagonists - therapeutic use | Quality of Life | Aged | Androgen Antagonists - adverse effects | Adenocarcinoma - mortality | Treatment outcome | Development and progression | Drug therapy | Prostate cancer | Analysis | Nuclear magnetic resonance--NMR | Medical imaging | Research & development--R&D | Clinical trials | Oncology | Metastasis | Radiation therapy | Patients | Cancer therapies | Survival | Evidence-based medicine | Metastases | Androgens | Chemotherapy | Pain | Castration | Pharmaceuticals | Urologi och njurmedicin | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap | Urology and Nephrology
Journal Article